ImmunityBio Securities Fraud Class Action Targets Cancer Drug ClaimsMay 16, 2026Law and PolicyA securities fraud class action filed May 11 targets ImmunityBio and CEO Patrick Soon-Shiong over alleged false claims that cancer drug Anktiva was a vaccine.
ImmunityBio Faces Securities Fraud Class Action Over Two-Month Trading WindowMay 8, 2026Law and PolicyA securities fraud class action filed against ImmunityBio Inc. in the Central District of California covers a narrow two-month trading window, with a lead plaintiff deadline of May 26, 2026.
ImmunityBio Faces Securities Fraud Class Action Over Cancer Drug ClaimsMay 4, 2026Law and PolicyA securities fraud class action filed against ImmunityBio targets executive Patrick Soon-Shiong's claim that cancer drug Anktiva is a vaccine, a description the FDA rejected.